Endogenex Secures $50 Million for Groundbreaking Diabetes Treatment
March 31, 2026, 3:34 pm
Endogenex, a cutting-edge medical technology firm, recently closed a $50 million Series C extension funding round. This significant investment pushes its total Series C financing to an impressive $138 million. The capital infusion propels the development of its innovative ReCET System. This minimally invasive procedure targets Type 2 Diabetes. It utilizes non-thermal pulsed electric fields. The technology aims to regenerate duodenal tissue. This process seeks to restore critical metabolic signaling. It represents a novel approach to disease modification. These funds are vital. They will complete pivotal clinical studies. They will also accelerate the FDA regulatory pathway. Endogenex endeavors to revolutionize diabetes care. It focuses on addressing underlying causes, moving beyond mere symptom management. This funding marks a pivotal step toward FDA approval and broader patient access. The company's FDA Breakthrough Device Designation highlights its profound potential impact. This investment ensures crucial research and development efforts continue uninterrupted. It promises new hope for millions globally suffering from Type 2 Diabetes.
Endogenex, a Minneapolis-based medical technology company, has secured substantial new funding. The company raised $50 million in a Series C extension round. This brings its total Series C financing to $138 million. The initial $88 million Series C closed in June 2024. Arboretum Ventures led this latest extension. Existing investors also participated. This capital boost fuels continued clinical development and regulatory advancements.
The newly acquired funds hold clear strategic importance. They will complete the pivotal ReCET Clinical Study. They will also propel the company's technology through the U.S. Food and Drug Administration (FDA) approval process. Endogenex plans to expand its operations. Research and development efforts will also intensify. The company focuses on a critical unmet need in diabetes care. It aims to offer a transformative treatment option.
At the core of Endogenex's mission lies its innovative ReCET System. This system represents a minimally invasive, outpatient endoscopic procedure. It specifically targets Type 2 Diabetes. The approach addresses the duodenum, the first section of the small intestine. It applies highly controlled, non-thermal pulsed electric fields. These fields interact with the mucosa and submucosa of the duodenal tissue. This process encourages healthy cell regeneration. It seeks to restore proper metabolic signaling from the gut.
The scientific premise behind the ReCET System is compelling. Growing evidence suggests duodenal inflammation disrupts communication. This disruption occurs between the gut and other organs. These organs are crucial for metabolic control. This imbalance may contribute significantly to Type 2 Diabetes progression. By targeting this underlying pathology, Endogenex aims to go beyond symptom management. It strives to alter the disease course itself. This represents a significant paradigm shift in diabetes treatment.
Type 2 Diabetes remains a global health crisis. Millions struggle with inadequately controlled blood glucose levels. Current therapies often manage symptoms. They do not always address root causes. The Endogenex System offers a potential solution. It aims to restore physiological function. This could reduce reliance on ongoing medication. It promises improved long-term patient outcomes. The focus is on reversing underlying cellular damage.
The ReCET System has already demonstrated promising results in earlier studies. Feasibility studies include REGENT-1 US, REGENT-1 Australia, and EMINENT in the Netherlands. Preliminary outcomes from these studies have been presented at medical conferences worldwide. These initial findings support the technology's safety and efficacy profile. They pave the way for more extensive clinical evaluation.
The company is now deep into its pivotal ReCET Clinical Study. This study is multicenter, randomized, and double-blinded. It features a sham-controlled design. Its primary objective is evaluating the safety and effectiveness of the Endogenex System. The study received Investigational Device Exemption (IDE) approval in November 2023. It is actively enrolling participants across clinical sites in both the United States and Australia. Successful completion of this study is crucial for regulatory approval.
Endogenex operates with a strong regulatory advantage. The FDA granted the Endogenex System Breakthrough Device Designation. This designation applies to treating Type 2 Diabetes in adults. Specifically, it targets those whose blood glucose levels are inadequately controlled by existing glucose-lowering medications. This status accelerates the review process. It also signifies the FDA's recognition of the technology's potential. Breakthrough devices offer more effective treatment for life-threatening or irreversibly debilitating diseases.
The company was founded in partnership with the Mayo Clinic. This collaboration underscores its commitment to scientific rigor. It also highlights its dedication to medical innovation. CEO Stacey Pugh leads Endogenex. Her leadership drives the company's mission. The goal is developing therapies. These therapies address the fundamental causes of Type 2 Diabetes. The company seeks to provide lasting solutions, not just temporary relief.
This recent financing solidifies Endogenex's position. It allows them to complete critical clinical milestones. It supports their journey towards FDA approval. The ReCET System offers a potential new tool for gastroenterologists and endocrinologists. It addresses a disease affecting hundreds of millions globally. Endogenex aims to provide a transformative option for patients. This new funding brings that goal significantly closer. The future of diabetes treatment may soon look very different.
Endogenex, a Minneapolis-based medical technology company, has secured substantial new funding. The company raised $50 million in a Series C extension round. This brings its total Series C financing to $138 million. The initial $88 million Series C closed in June 2024. Arboretum Ventures led this latest extension. Existing investors also participated. This capital boost fuels continued clinical development and regulatory advancements.
The newly acquired funds hold clear strategic importance. They will complete the pivotal ReCET Clinical Study. They will also propel the company's technology through the U.S. Food and Drug Administration (FDA) approval process. Endogenex plans to expand its operations. Research and development efforts will also intensify. The company focuses on a critical unmet need in diabetes care. It aims to offer a transformative treatment option.
At the core of Endogenex's mission lies its innovative ReCET System. This system represents a minimally invasive, outpatient endoscopic procedure. It specifically targets Type 2 Diabetes. The approach addresses the duodenum, the first section of the small intestine. It applies highly controlled, non-thermal pulsed electric fields. These fields interact with the mucosa and submucosa of the duodenal tissue. This process encourages healthy cell regeneration. It seeks to restore proper metabolic signaling from the gut.
The scientific premise behind the ReCET System is compelling. Growing evidence suggests duodenal inflammation disrupts communication. This disruption occurs between the gut and other organs. These organs are crucial for metabolic control. This imbalance may contribute significantly to Type 2 Diabetes progression. By targeting this underlying pathology, Endogenex aims to go beyond symptom management. It strives to alter the disease course itself. This represents a significant paradigm shift in diabetes treatment.
Type 2 Diabetes remains a global health crisis. Millions struggle with inadequately controlled blood glucose levels. Current therapies often manage symptoms. They do not always address root causes. The Endogenex System offers a potential solution. It aims to restore physiological function. This could reduce reliance on ongoing medication. It promises improved long-term patient outcomes. The focus is on reversing underlying cellular damage.
The ReCET System has already demonstrated promising results in earlier studies. Feasibility studies include REGENT-1 US, REGENT-1 Australia, and EMINENT in the Netherlands. Preliminary outcomes from these studies have been presented at medical conferences worldwide. These initial findings support the technology's safety and efficacy profile. They pave the way for more extensive clinical evaluation.
The company is now deep into its pivotal ReCET Clinical Study. This study is multicenter, randomized, and double-blinded. It features a sham-controlled design. Its primary objective is evaluating the safety and effectiveness of the Endogenex System. The study received Investigational Device Exemption (IDE) approval in November 2023. It is actively enrolling participants across clinical sites in both the United States and Australia. Successful completion of this study is crucial for regulatory approval.
Endogenex operates with a strong regulatory advantage. The FDA granted the Endogenex System Breakthrough Device Designation. This designation applies to treating Type 2 Diabetes in adults. Specifically, it targets those whose blood glucose levels are inadequately controlled by existing glucose-lowering medications. This status accelerates the review process. It also signifies the FDA's recognition of the technology's potential. Breakthrough devices offer more effective treatment for life-threatening or irreversibly debilitating diseases.
The company was founded in partnership with the Mayo Clinic. This collaboration underscores its commitment to scientific rigor. It also highlights its dedication to medical innovation. CEO Stacey Pugh leads Endogenex. Her leadership drives the company's mission. The goal is developing therapies. These therapies address the fundamental causes of Type 2 Diabetes. The company seeks to provide lasting solutions, not just temporary relief.
This recent financing solidifies Endogenex's position. It allows them to complete critical clinical milestones. It supports their journey towards FDA approval. The ReCET System offers a potential new tool for gastroenterologists and endocrinologists. It addresses a disease affecting hundreds of millions globally. Endogenex aims to provide a transformative option for patients. This new funding brings that goal significantly closer. The future of diabetes treatment may soon look very different.